Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Pyeloplasty in Pediatric Patients With Differential Renal Function Less Than 10%

NCT07836621 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2026-06-01
Last updated
2026-09-23

Condition(s) studied

PyeloplastyPediatric PatientsDifferential Renal Function

Investigational drug(s) / intervention(s)

Pyeloplasty

Pyeloplasty: Patients will undergo Anderson-Hynes dismembered pyeloplasty for primary ureteropelvic junction obstruction. The procedure was performed through an open, laparoscopic, or mini-incision approach according to the patient's age and the surgeon's clinical judgment. A ureteral stent was inserted when indicated.

Study summary

This study aims to evaluate the postoperative outcomes of pyeloplasty in pediatric patients presenting with ureteropelvic junction obstruction and preoperative differential renal function less than 10%, focusing on:

* Improvement or stabilization of renal function after surgery.
* Radiological improvement in hydronephrosis.
* Clinical outcomes such as symptom relief and complication rates.

Eligibility

Sex
ALL
Min age
1 Month
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 1 month to 18 years. * Diagnosis of primary ureteropelvic junction obstruction. * Preoperative differential renal function \<10% on MAG3 renogram. * A normal contralateral kidney. Exclusion Criteria: * Secondary Ureteropelvic Junction Obstruction (UPJO) (postoperative, traumatic, or secondary to other anomalies). * Solitary functioning kidney. * Associated vesicoureteral reflux or posterior urethral valves. * Severe comorbidities affecting renal function. * Incomplete medical records.

Primary outcome measure(s)

  • Change in Differential Renal Function After Pyeloplasty — 6 months after pyeloplasty
    Differential renal function of the affected kidney will be assessed using MAG-3 diuretic renography. Renal function will be classified as improved when differential renal function increases by at least 5 percentage points, stable when the change is less than 5 percentage points in either direction, and deteriorated when it decreases by at least 5 percentage points.

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta El-Gharbia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07836621 on ClinicalTrials.gov ↗ ← All trials in Egypt